September 9, 2015
September 9th, 2015 - Terumo Corporation （Headquarters: Shibuya-ku, Tokyo, Japan; President: Yutaro Shintaku） and Quirem Medical B.V., a commercial stage Dutch medical technology company that focuses on radioembolization, today announced that Terumo has made an equity investments in Quirem Medical.
Quirem Medical develops QuiremSpheres, next generation microspheres for the radioembolization treatment of liver cancer, which was developed by the University Medical Center （UMC） Utrecht, and received the European CE mark for quality and safety earlier this year.
Peter Coenen, president of Terumo Europe Interventional Systems, commented: "QuiremSpheres could be a good fit with the product portfolio offered by Terumo to interventional oncologists and interventional doctors in their treatment of cancer patients."
Jan Sigger, CEO of Quirem Medical, commented: "We consider our holmium microspheres as 'the next generation microspheres for radioembolization', as they can be visualized by both MRI scans and SPECT-CT, allowing customized treatment for each individual patient. We are confident that the investment by Terumo will accelerate our global expansion, reflecting our ambition to make our technology available to patients around the world."
Professor Maurice van den Bosch, head of Radiology University Centre Utrecht, commented: "We congratulate Quirem Medical and Terumo with their strategic partnership. Over the last 15 years the Holmium microsphere technology, on which the QuiremSpheres are based, have been successfully developed within the University Medical Centre Utrecht. I am confident that our strategic collaboration with Quirem Medical will strongly benefit from the additional capabilities invested by Terumo".
Tokyo-based Terumo Corporation is one of the world's leading medical device manufacturers with over $4 billion in sales and operations in more than 160 nations. Founded in 1921, the company develops, manufactures, and distributes world-class medical devices including products for use in interventional procedures, cardiovascular surgery, and transfusion medicine; the company also manufactures a broad array of syringe and hypodermic needle products for hospital and physician office use and also supplies drug delivery/injection devices to pharmaceutical firms. Terumo Corporation's shares are listed on the first section of the Tokyo Stock Exchange and are a component of the Nikkei, Japan's leading stock index.
Quirem Medical is an emerging medical device company with a mission to develop the next generation microspheres for targeted interventional oncology solutions.
Corporate Communication Dept., Terumo Corporation
(Notice) Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts on projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition. The market share information in this press release is partly derived from our own independent research.